

## LIBERIA

### Support for Inactivated Polio Virus Vaccine

This Decision Letter sets out the Programme Terms of a Programme

<b>1. Country:</b> Liberia																
<b>2. Vaccine grant number:</b>		15-LBR-08h-Y, 1518-LBR-25c-X, 19-LBR-25c-X, 20-LBR-25b-X														
<b>3. Date of Decision Letter:</b>		30-Sep-2019														
<b>4. Date of the Partnership Framework Agreement:</b>		19 August 2013														
<b>5. Programme title:</b>		New Vaccine Support (NVS), Inactivated Polio Virus, Routine														
<b>6. Vaccine type:</b>		Inactivated Polio Virus														
<b>7. Requested product presentation and formulation of vaccine:</b> Inactivated Polio Vaccine, 5 doses per vial, LIQUID																
<b>8. Programme Duration:</b> <sup>1</sup> 2015-2020																
<b>9. Programme Budget (indicative):</b> <sup>2</sup> (subject to the terms of the Partnership Framework Agreement, if applicable)																
	<b>2015-2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>	<b>2024</b>	<b>Total</b> <sup>2</sup>									
Programme Budget (US\$)	596,639	191,500	-	-	-	-	788,139									
<b>10. Vaccine introduction grant</b>																
<table border="1" style="margin: auto;"> <tr><th colspan="3">Approval</th></tr> <tr><th>Year</th><th>Grant Number</th><th>Amount (US\$)</th></tr> <tr><td>2015</td><td>15-LBR-08h-Y</td><td style="text-align: right;">125,000</td></tr> </table>								Approval			Year	Grant Number	Amount (US\$)	2015	15-LBR-08h-Y	125,000
Approval																
Year	Grant Number	Amount (US\$)														
2015	15-LBR-08h-Y	125,000														
<table border="1" style="margin: auto;"> <tr><th colspan="2">Disbursement</th></tr> <tr><th>Disbursement date</th><th>Amount (US\$)</th></tr> <tr><td>25 July, 2014</td><td style="text-align: right;">125,000</td></tr> </table>								Disbursement		Disbursement date	Amount (US\$)	25 July, 2014	125,000			
Disbursement																
Disbursement date	Amount (US\$)															
25 July, 2014	125,000															
<b>11. Product switch grant</b>																
Not applicable																
<b>12. Indicative Annual Amounts:</b> <sup>3</sup> (subject to the terms of the Partnership Framework Agreement, if applicable)																
<b>Type of supplies to be purchased with Gavi funds</b>	<b>2015-2019</b>	<b>2020</b>	<b>2021</b>													

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the amount that Gavi has approved.

Number of vaccine doses		70,500	-												
Annual Amounts (US\$)	596,639	191,500	-												
<b>13. Procurement agency:</b>	UNICEF. The Country shall release its co-financing payments each year to UNICEF.														
<b>14. Self-procurement:</b>	Not applicable														
<b>15. Co-financing obligations:</b>	<p>Not applicable</p> <p>Gavi's usual co-financing requirements do not apply to IPV. However, the Country is encouraged to contribute to vaccine and/or supply costs for IPV.</p>														
<b>16. Operational support for campaigns:</b>	The support for operational costs for the IPV catch-up campaign of US\$ 120,900 was disbursed in June 2019														
<b>17. Additional Reporting Requirements:</b>	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</td> <td></td> </tr> <tr> <td> <ul style="list-style-type: none"> <li>Vaccine stock levels including buffer stock</li> </ul> </td> <td>31 March 2020</td> </tr> <tr> <td> <ul style="list-style-type: none"> <li>Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received</li> </ul> </td> <td>15 May 2020</td> </tr> <tr> <td> <ul style="list-style-type: none"> <li>Country shall report the actual switch date in the first renewal request following the actual implementation</li> </ul> </td> <td></td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>				Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year:		<ul style="list-style-type: none"> <li>Vaccine stock levels including buffer stock</li> </ul>	31 March 2020	<ul style="list-style-type: none"> <li>Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received</li> </ul>	15 May 2020	<ul style="list-style-type: none"> <li>Country shall report the actual switch date in the first renewal request following the actual implementation</li> </ul>		In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
	Due dates														
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:															
<ul style="list-style-type: none"> <li>Vaccine stock levels including buffer stock</li> </ul>	31 March 2020														
<ul style="list-style-type: none"> <li>Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received</li> </ul>	15 May 2020														
<ul style="list-style-type: none"> <li>Country shall report the actual switch date in the first renewal request following the actual implementation</li> </ul>															
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat														
<b>18. Financial clarifications:</b>	Not applicable														
<b>19. Other:</b>	<p>Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.</p>														

Signed by,  
On behalf of Gavi



Thabani Maphosa,  
Managing Director, Country Programmes  
30-Sep-2019